Haemonetics (NYSE:HAE) Upgraded by Wall Street Zen to Strong-Buy Rating

Wall Street Zen upgraded shares of Haemonetics (NYSE:HAE) from a buy rating to a strong-buy rating in a research note published on Saturday.

HAE has been the topic of a number of other reports. Weiss Ratings upgraded Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, June 25th. Barrington Research set a $95.00 target price on Haemonetics in a report on Friday. BTIG Research boosted their target price on shares of Haemonetics from $84.00 to $96.00 and gave the stock a “buy” rating in a research report on Thursday. Robert W. Baird set a $96.00 price target on shares of Haemonetics in a research note on Friday. Finally, Raymond James Financial reiterated an “outperform” rating and issued a $105.00 price target on shares of Haemonetics in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.89.

Haemonetics Trading Up 2.9%

Shares of Haemonetics stock opened at $87.50 on Friday. The firm has a market cap of $3.98 billion, a price-to-earnings ratio of 42.89, a price-to-earnings-growth ratio of 1.77 and a beta of 0.52. Haemonetics has a 52-week low of $47.31 and a 52-week high of $88.58. The company’s 50-day simple moving average is $76.98 and its 200-day simple moving average is $66.52. The company has a quick ratio of 1.87, a current ratio of 3.08 and a debt-to-equity ratio of 1.40.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%.The company had revenue of $339.38 million for the quarter, compared to analyst estimates of $327.86 million. During the same quarter in the previous year, the company earned $1.10 EPS. The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. As a group, equities research analysts anticipate that Haemonetics will post 5.21 earnings per share for the current year.

Institutional Trading of Haemonetics

Several large investors have recently bought and sold shares of the company. Kemnay Advisory Services Inc. purchased a new position in shares of Haemonetics in the fourth quarter valued at $26,000. Leonteq Securities AG purchased a new stake in shares of Haemonetics in the 4th quarter worth about $30,000. EverSource Wealth Advisors LLC grew its stake in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 396 shares during the last quarter. Kestra Advisory Services LLC acquired a new stake in Haemonetics in the 4th quarter valued at about $34,000. Finally, Bayforest Capital Ltd purchased a new position in Haemonetics during the 4th quarter valued at about $40,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Key Stories Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Haemonetics reported fiscal Q1 2027 earnings of $1.14 per share, exceeding the $1.07–$1.08 consensus range. Revenue rose 5.5% year over year to $339.4 million, also comfortably ahead of expectations near $327.9 million. The earnings and sales beats indicate continued operating momentum. Haemonetics Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2027 outlook and now expects reported revenue growth of approximately 5% to 8%. The improved forecast, following a strong first quarter, supports the view that demand and execution are better than previously anticipated. Haemonetics Raises Fiscal 2027 Revenue Guidance
• Positive Sentiment: BTIG Research raised its Haemonetics price target from $84 to $96 and maintained a “buy” rating, implying additional upside based on the company’s earnings performance and outlook. BTIG Raises Haemonetics Price Target
• Neutral Sentiment: Citigroup lifted its price target from $79 to $92, while retaining a “neutral” rating. The higher target reflects improved estimates but suggests limited conviction at the current valuation. Citigroup Analyst Update
• Neutral Sentiment: JPMorgan raised its target from $62 to $86 but maintained a “neutral” rating. The revised target remains slightly below the recent trading level, signaling that valuation may constrain further gains despite the improved outlook. JPMorgan Analyst Update

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.